| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
63,980,000 |
| Market
Cap: |
610.37(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$8.22 - $11.59 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 18.6 |
| Insider 6 Months : 18.6 |
| Insider 3/6 Months : 37.7 |
|
| Guru Rank Number : 245 |
| Guru Rank Value : 4.8 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Theravance Biopharma is a biopharmaceutical company primarily focused on the discovery, development and commercialization of respiratory medicine medicines. Co.'s program include: YUPELRI™ (revefenacin) inhalation solution, nebulized long-acting muscarinic antagonist for the maintenance treatment of chronic obstructive pulmonary disease; and Lung-selective, Nebulized Pan-Janus Kinase (JAK) Inhibitor (Nezulcitinib), a lung-selective, nebulized JAK inhibitor, in clinical development for the potential treatment of hospitalized patients with acute lung injury caused by Coronavirus Disease 2019.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
1,499,124 |
1,499,124 |
1,499,124 |
1,499,124 |
| Total Buy Value |
$13,117,335 |
$13,117,335 |
$13,117,335 |
$13,117,335 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
1 |
1 |
1 |
| Total Shares Sold |
1,254 |
5,114 |
22,963 |
172,089 |
| Total Sell Value |
$10,922 |
$50,468 |
$231,475 |
$1,835,193 |
| Total People Sold |
1 |
2 |
2 |
4 |
| Total Sell Transactions |
1 |
3 |
11 |
21 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Molineaux Susan |
Director |
– • – |
2018-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
8,186 |
14,186 |
|
- |
|
| Ringrose Peter S |
Director |
– • – |
2018-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
8,186 |
29,614 |
|
- |
|
| Malkiel Burton G |
Director |
– • – |
2018-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
8,186 |
55,757 |
|
- |
|
| Whitesides George M |
Director |
– • – |
2018-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
8,186 |
192,578 |
|
- |
|
| Broshy Eran |
Director |
– • – |
2018-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
8,186 |
26,186 |
|
- |
|
| Gunderson Robert V Jr |
Director |
– • – |
2018-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
8,186 |
43,245 |
|
- |
|
| Young William D |
Director |
– • – |
2018-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
8,186 |
43,310 |
|
- |
|
| Mitchell Dean J |
Director |
– • – |
2018-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
8,186 |
26,186 |
|
- |
|
| Oconnor Donal |
Director |
– • – |
2018-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
8,186 |
23,186 |
|
- |
|
| Smaldone Alsup Laurie |
Director |
– • – |
2018-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
8,186 |
9,962 |
|
- |
|
| Worboys Philip D |
SVP, Translational Science |
• – – |
2018-02-20 |
4 |
D |
$29.09 |
$132,825 |
D/D |
(4,566) |
163,563 |
|
- |
|
| Suliman Shehnaaz |
SVP, Corp Dev & Strategy |
• – – |
2018-02-20 |
4 |
D |
$29.09 |
$255,119 |
D/D |
(8,770) |
101,230 |
|
- |
|
| Shafer Bradford J |
EVP, Gen. Counsel, Secretary |
• – – |
2018-02-20 |
4 |
D |
$29.09 |
$162,526 |
D/D |
(5,587) |
130,661 |
|
- |
|
| Pitzer Kenneth R |
SVP, Prod Strat & Comm Plng |
• – – |
2018-02-20 |
4 |
D |
$29.09 |
$123,691 |
D/D |
(4,252) |
152,054 |
|
- |
|
| Haumann Brett K |
SVP Clin Dev & Chief Med Ofc |
• – – |
2018-02-20 |
4 |
D |
$29.09 |
$241,243 |
D/D |
(8,293) |
142,203 |
|
- |
|
| Winningham Rick E |
Chief Executive Officer |
• • – |
2018-02-20 |
4 |
D |
$29.09 |
$378,315 |
D/D |
(13,005) |
881,372 |
|
- |
|
| Pasqualone Frank |
SVP, Chief Comm Ops Officer |
• – – |
2018-02-20 |
4 |
D |
$29.09 |
$137,916 |
D/D |
(4,741) |
211,619 |
|
- |
|
| Gala Renee D |
SVP, Chief Financial Officer |
• – – |
2018-02-20 |
4 |
D |
$29.09 |
$156,708 |
D/D |
(5,387) |
211,407 |
|
- |
|
| Hegde Sharathchandra S |
SVP, Research |
• – – |
2018-02-20 |
4 |
D |
$29.09 |
$126,512 |
D/D |
(4,349) |
159,611 |
|
- |
|
| Smaldone Alsup Laurie |
Director |
– • – |
2018-02-13 |
4 |
A |
$0.00 |
$0 |
D/D |
1,776 |
1,776 |
|
- |
|
| Suliman Shehnaaz |
SVP, Corp Dev & Strategy |
• – – |
2018-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
90,000 |
110,000 |
|
- |
|
| Pasqualone Frank |
SVP, Chief Comm Ops Officer |
• – – |
2018-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
216,360 |
|
- |
|
| Haumann Brett K |
SVP Clin Dev & Chief Med Ofc |
• – – |
2018-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
150,496 |
|
- |
|
| Pitzer Kenneth R |
SVP, Prod Strat & Comm Plng |
• – – |
2018-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
156,306 |
|
- |
|
| Worboys Philip D |
SVP, Translational Science |
• – – |
2018-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
168,129 |
|
- |
|
530 Records found
|
|
Page 14 of 22 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.06 (0.63%) 
